KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Total Non-Current Liabilities: 2009-2024

Historic Total Non-Current Liabilities for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $6.8 billion.

  • Regeneron Pharmaceuticals' Total Non-Current Liabilities rose 11.83% to $7.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 billion, marking a year-over-year increase of 11.83%. This contributed to the annual value of $6.8 billion for FY2024, which is 9.30% up from last year.
  • Regeneron Pharmaceuticals' Total Non-Current Liabilities amounted to $6.8 billion in FY2024, which was up 9.30% from $6.3 billion recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' Total Non-Current Liabilities registered a high of $6.8 billion during FY2024, and its lowest value of $5.5 billion during FY2020.
  • In the last 3 years, Regeneron Pharmaceuticals' Total Non-Current Liabilities had a median value of $6.3 billion in 2023 and averaged $6.3 billion.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Total Non-Current Liabilities soared by 72.67% in 2020, and later fell by 1.22% in 2022.
  • Over the past 5 years, Regeneron Pharmaceuticals' Total Non-Current Liabilities (Yearly) stood at $5.5 billion in 2020, then climbed by 9.81% to $6.0 billion in 2021, then declined by 1.22% to $5.9 billion in 2022, then rose by 5.76% to $6.3 billion in 2023, then grew by 9.30% to $6.8 billion in 2024.